drugset
drugset / Trial / NCT06237413

A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours

NCT06237413 ↗

Phase 1/2 Unknown 110 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.

Timeline

Start
2023-08-10
Primary completion
2026-02
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ZG2001 Unknown 50 mg Oral
Subject ZG2001 Unknown 100 mg Oral
Subject ZG2001 Unknown 200 mg Oral

Indications

cancer